Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.
Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...
1don MSN
Whoopi Goldberg has warned fans about a fake advertisement, which features an AI-edited video of her endorsing a weight loss ...
Pharmaceutical Technology on MSN7h
Novo Nordisk plans new study for CagriSema, targets 2026 submissionCagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...
The prevalence of obesity in India was lower than in other countries but now it's increasing, Rachel Batterham, senior vice ...
US pharma major Eli Lilly today announced its financial results for the fourth quarter of 2024 and detailed 2025 financial ...
The number of Netherlands residents using medicines like Ozempic, Wegovy, and Mounjaro for weight loss is increasing ...
The use of weight loss drugs like Ozempic and Wegovy is growing in the Netherlands as more people opt to pay for ...
A damaging trial failure in December wiped 70% off the share price of BioAge Labs, a US biopharma developing therapeutic ...
SLOWLY lifting her head off her sweat-drenched pillow, Aisleyne Horgan-Wallace vomits into the sick bucket next to her bed. ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback